Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

NCT05190094 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Interventions

DRUG: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

Sponsor

International Cancer Research Group, United Arab Emirates

Collaborators

[object Object]
[object Object]
[object Object]